ABBVIE
🇫🇷France
BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
Phase 3
Completed
- Conditions
- Psoriasis
- Interventions
- First Posted Date
- 2016-02-18
- Last Posted Date
- 2021-08-23
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 577
- Registration Number
- NCT02684357
BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
Phase 3
Completed
- Conditions
- Psoriasis
- Interventions
- First Posted Date
- 2016-02-18
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 560
- Registration Number
- NCT02684370
A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone
- First Posted Date
- 2016-02-05
- Last Posted Date
- 2023-04-11
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 661
- Registration Number
- NCT02675426
- Locations
- 🇪🇸
Hospital Clin Univ San Carlos /ID# 138993, Madrid, Spain
🇺🇸Houston Institute for Clin Res /ID# 138716, Houston, Texas, United States
🇧🇪AZ Sint Lucas /ID# 141338, Brugge, Belgium
Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer
- First Posted Date
- 2016-02-04
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 342
- Registration Number
- NCT02674568
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
- First Posted Date
- 2016-02-03
- Last Posted Date
- 2019-10-09
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 507
- Registration Number
- NCT02672852
Observational, Multi-Center Study of the Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in the Russian Federation
Completed
- Conditions
- Genotype 1Chronic Hepatitis C
- First Posted Date
- 2016-02-01
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 158
- Registration Number
- NCT02669940
Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: Adalimumab
- First Posted Date
- 2016-01-29
- Last Posted Date
- 2019-09-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 55
- Registration Number
- NCT02668640
Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women
Phase 3
Completed
- Conditions
- Uterine FibroidsHeavy Menstrual Bleeding
- Interventions
- Drug: ElagolixDrug: Placebo for Estradiol/Norethindrone AcetateDrug: Estradiol/Norethindrone AcetateDrug: Placebo for Elagolix
- First Posted Date
- 2016-01-13
- Last Posted Date
- 2020-06-29
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 413
- Registration Number
- NCT02654054
- Locations
- 🇺🇸
Houston Ctr for Clin Research /ID# 149149, Sugar Land, Texas, United States
🇺🇸Fellows Research Alliance, Inc /ID# 139655, Savannah, Georgia, United States
🇺🇸University of California, Los Angeles /ID# 144107, Los Angeles, California, United States
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection
Phase 3
Completed
- Conditions
- Chronic Hepatitis C Virus (HCV) Infection
- Interventions
- Drug: ABT-493/ABT-530
- First Posted Date
- 2016-01-08
- Last Posted Date
- 2017-10-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 104
- Registration Number
- NCT02651194
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis
Phase 3
Completed
- Conditions
- Compensated CirrhosisChronic Hepatitis CHepatitis C Virus Infection
- Interventions
- Drug: ABT-493/ABT-530
- First Posted Date
- 2015-12-30
- Last Posted Date
- 2021-07-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 146
- Registration Number
- NCT02642432
© Copyright 2025. All Rights Reserved by MedPath